Credit Suisse Ag Cullinan Oncology, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 45,755 shares of CGEM stock, worth $391,205. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,755

Previous 42,902 6.65%

Holding current value

$391,205

Previous $437,000 78.26%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$10.17 - $19.02 $29,015 - $54,264	2,853 Added 6.65%	45,755 $779,000
Q4 2023 Feb 08, 2024	BUY	$7.89 - $10.23 $184,807 - $239,617	23,423 Added 120.25%	42,902 $437,000
Q3 2023 Nov 13, 2023	SELL	$9.05 - $11.72 $5,692 - $7,371	-629 Reduced 3.13%	19,479 $176,000
Q2 2023 Aug 11, 2023	BUY	$8.8 - $13.4 $82,350 - $125,397	9,358 Added 87.05%	20,108 $216,000
Q1 2023 May 10, 2023	BUY	$10.2 - $11.91 $30 - $35	3 Added 0.03%	10,750 $109,000

Q4 2022 Feb 13, 2023	BUY	$9.72 - $13.62 $1,788 - $2,506	184 Added 1.74%	10,747 $113,000
Q3 2022 Nov 10, 2022	BUY	$11.82 - $15.42 $1,702 - $2,220	144 Added 1.38%	10,563 $135,000
Q2 2022 Aug 12, 2022	SELL	$7.31 - $13.55 $14,400 - $26,693	-1,970 Reduced 15.9%	10,419 $134,000
Q1 2022 May 16, 2022	SELL	$10.47 - $16.75 $8,355 - $13,366	-798 Reduced 6.05%	12,389 $131,000
Q4 2021 Feb 14, 2022	BUY	$15.36 - $25.0 $56,110 - $91,325	3,653 Added 38.32%	13,187 $204,000
Q3 2021 Nov 12, 2021	BUY	$22.56 - $29.68 $11,347 - $14,929	503 Added 5.57%	9,534 $215,000
Q2 2021 Aug 16, 2021	BUY	$24.96 - $41.25 $225,413 - $372,528	9,031 New	9,031 $233,000

Others Institutions Holding CGEM

# of Institutions

149

Shares Held

65.1M

Call Options Held

10.7K

Put Options Held

14.4K

View Full List

About Cullinan Oncology, Inc.

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $390M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

More about CGEM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account